retatrutide dose trial Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Retatrutide—A Game Changer in Obesity

Whilst GLP-1 receptor agonists demonstrate favourable efficacy for weight loss, they are not suitable for everyone and carry potential adverse effects that require careful consideration and monitoring

Commonly reported side effects in the Phase 2 trial included: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea Constipation Decreased appetite Abdominal discomfort or bloating Eructation (belching) The majority of participants who discontinued treatment did so due to gastrointestinal side effects, underscoring the importance of the slow titration schedule used in trials

Ghigo, E., Arvat, E., Gianotti, L., Imbimbo, B

30 In addition, reductions in body fat may affect plasma cystatin C levels without real changes in GFR because cystatin C is mainly produced in adipose tissue

Possible confounding factors in patients include co-existing pathologies and treatments, lack of selection of treatments according to ROS levels, among others